These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

71 related articles for article (PubMed ID: 8729586)

  • 1. Safety profile of fluvastatin.
    Peters TK
    Br J Clin Pract Suppl; 1996 Jan; 77A():20-3. PubMed ID: 8729586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety profile of fluvastatin.
    Peters TK
    Br J Clin Pract Suppl; 1994 Dec; (77):20-3. PubMed ID: 19489170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of efficacy and safety assessment of fluvastatin in patients <65 years versus > or =65 years of age.
    Bruckert E; Verpilleux MP; Dejager S; Isaacsohn J
    Am J Cardiol; 2005 Oct; 96(8):1142-8. PubMed ID: 16214453
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluvastatin in combination with other lipid-lowering agents.
    Jokubaitis LA
    Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials.
    Winkler K; Ablethauser CB; Gimpelewicz C; Bortolini M; Isaacsohn JL
    Clin Ther; 2007 Sep; 29(9):1987-2000. PubMed ID: 18035198
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.
    Silva M; Matthews ML; Jarvis C; Nolan NM; Belliveau P; Malloy M; Gandhi P
    Clin Ther; 2007 Feb; 29(2):253-60. PubMed ID: 17472818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluvastatin treatment is not associated with an increased incidence of cancer.
    Stein EA; Corsini A; Gimpelewicz CR; Bortolini M; Gil M
    Int J Clin Pract; 2006 Sep; 60(9):1028-34. PubMed ID: 16939542
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The renal safety profile of fluvastatin: results of a pooled analysis.
    Holdaas H; Wanner C; Abletshauser C; Gimpelewicz C; Isaacsohn J
    Ren Fail; 2006; 28(6):487-92. PubMed ID: 16928618
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of fluvastatin on cardiac outcomes in kidney transplant patients with systemic lupus erythematosus: a randomized placebo-controlled study.
    Norby GE; Holme I; Fellström B; Jardine A; Cole E; Abedini S; Holdaas H;
    Arthritis Rheum; 2009 Apr; 60(4):1060-4. PubMed ID: 19333947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
    Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
    Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of the lipid-modifying efficacy and safety profiles of ezetimibe coadministered with simvastatin in older versus younger patients with primary hypercholesterolemia: a post Hoc analysis of subpopulations from three pooled clinical trials.
    Feldman T; Davidson M; Shah A; Maccubbin D; Meehan A; Zakson M; Tribble D; Veltri E; Mitchel Y
    Clin Ther; 2006 Jun; 28(6):849-59. PubMed ID: 16860168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of fluvastatin on cardiac outcomes in patients with moderate to severe renal insufficiency: a pooled analysis of double-blind, randomized trials.
    Holdaas H; Wanner C; Abletshauser C; Gimpelewicz C; Isaacsohn J
    Int J Cardiol; 2007 Apr; 117(1):64-74. PubMed ID: 16889855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin.
    Skalicka B; Kubanek M; Malek I; Vymetalova Y; Hoskova L; Podzimkova M; Kautzner J
    J Heart Lung Transplant; 2009 Jun; 28(6):598-604. PubMed ID: 19481021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of dyslipidaemias with fluvastatin.
    Peters TK
    Br J Clin Pract Suppl; 1994 Dec; (77):16-9. PubMed ID: 19514133
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.
    Derosa G; Cicero AE; Bertone G; Piccinni MN; Ciccarelli L; Roggeri DE
    Clin Ther; 2004 Oct; 26(10):1599-607. PubMed ID: 15598476
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statin-related adverse events: a meta-analysis.
    Silva MA; Swanson AC; Gandhi PJ; Tataronis GR
    Clin Ther; 2006 Jan; 28(1):26-35. PubMed ID: 16490577
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked elevation of liver transaminases after high-dose fluvastatin unmasks chronic hepatitis C: safety and re-challenge.
    Chen YW; Lai HW; Wang TD
    Acta Neurol Taiwan; 2007 Sep; 16(3):163-7. PubMed ID: 17966956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
    Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
    Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study.
    Masana L; Mata P; Gagné C; Sirah W; Cho M; Johnson-Levonas AO; Meehan A; Troxell JK; Gumbiner B;
    Clin Ther; 2005 Feb; 27(2):174-84. PubMed ID: 15811480
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.